JP2022543059A5 - - Google Patents
Info
- Publication number
- JP2022543059A5 JP2022543059A5 JP2022506470A JP2022506470A JP2022543059A5 JP 2022543059 A5 JP2022543059 A5 JP 2022543059A5 JP 2022506470 A JP2022506470 A JP 2022506470A JP 2022506470 A JP2022506470 A JP 2022506470A JP 2022543059 A5 JP2022543059 A5 JP 2022543059A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- amino acid
- ccnd1
- acid sequence
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880504P | 2019-07-30 | 2019-07-30 | |
| US62/880,504 | 2019-07-30 | ||
| PCT/IB2020/057172 WO2021019472A1 (en) | 2019-07-30 | 2020-07-29 | T cell receptors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543059A JP2022543059A (ja) | 2022-10-07 |
| JP2022543059A5 true JP2022543059A5 (https=) | 2023-08-08 |
| JP7669346B2 JP7669346B2 (ja) | 2025-04-28 |
Family
ID=74228559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506470A Active JP7669346B2 (ja) | 2019-07-30 | 2020-07-29 | Ｔ細胞受容体及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12570715B2 (https=) |
| EP (1) | EP4004217A4 (https=) |
| JP (1) | JP7669346B2 (https=) |
| KR (1) | KR20220087431A (https=) |
| CN (1) | CN114555815B (https=) |
| AU (1) | AU2020320445A1 (https=) |
| BR (1) | BR112022001688A2 (https=) |
| CA (1) | CA3146298A1 (https=) |
| IL (1) | IL290227A (https=) |
| MX (1) | MX2022001209A (https=) |
| TW (1) | TWI881992B (https=) |
| WO (1) | WO2021019472A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3935175A4 (en) | 2019-03-04 | 2023-01-04 | University Health Network | T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF |
| KR20220087431A (ko) | 2019-07-30 | 2022-06-24 | 유니버시티 헬스 네트워크 | T 세포 수용체 및 이의 사용 방법 |
| US11672042B2 (en) * | 2020-11-03 | 2023-06-06 | At&T Intellectual Property I, L.P. | Endpoint device radio link failure information reporting |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1806358T1 (sl) * | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II |
| KR101363928B1 (ko) * | 2007-06-11 | 2014-02-19 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 특이적 유전자 발현 방법 |
| HUE032379T2 (en) * | 2007-07-27 | 2017-09-28 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP5736334B2 (ja) * | 2012-03-12 | 2015-06-17 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 無差別的にヒト白血球抗体（ｈｌａ）クラスｉｉ分子に結合する腫瘍関連ペプチド |
| CA3051222C (en) | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| DK3110975T3 (da) * | 2014-02-27 | 2021-10-11 | Jumpcode Genomics Inc | Fremgangsmåder til analyse af somatiske mobile elementer og anvendelser deraf |
| US20190119635A1 (en) | 2015-05-05 | 2019-04-25 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| AU2016306209B2 (en) * | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| JP2018532801A (ja) * | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
| WO2017173328A1 (en) | 2016-04-01 | 2017-10-05 | Baylor College Of Medicine | Methods of whole transcriptome amplification |
| WO2017185169A1 (en) | 2016-04-27 | 2017-11-02 | University Health Network (Uhn) | Pept1de-hla complexes and methods of producing same |
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| JP7328211B2 (ja) | 2017-04-24 | 2023-08-16 | オスペダーレ サン ラファエレ エス．アール．エル | Ｔｃｒ及びペプチド |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| KR20260026092A (ko) | 2017-09-19 | 2026-02-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
| TWI869426B (zh) | 2019-07-30 | 2025-01-11 | 大學健康網絡 | Ｔ細胞受體及其使用方法 |
| KR20220087431A (ko) | 2019-07-30 | 2022-06-24 | 유니버시티 헬스 네트워크 | T 세포 수용체 및 이의 사용 방법 |
| US20220275047A1 (en) | 2019-07-30 | 2022-09-01 | University Health Network | T cell receptors and methods of use thereof |
-
2020
- 2020-07-29 KR KR1020227006433A patent/KR20220087431A/ko active Pending
- 2020-07-29 WO PCT/IB2020/057172 patent/WO2021019472A1/en not_active Ceased
- 2020-07-29 CN CN202080061077.3A patent/CN114555815B/zh active Active
- 2020-07-29 JP JP2022506470A patent/JP7669346B2/ja active Active
- 2020-07-29 MX MX2022001209A patent/MX2022001209A/es unknown
- 2020-07-29 AU AU2020320445A patent/AU2020320445A1/en active Pending
- 2020-07-29 EP EP20845977.6A patent/EP4004217A4/en active Pending
- 2020-07-29 CA CA3146298A patent/CA3146298A1/en active Pending
- 2020-07-29 BR BR112022001688A patent/BR112022001688A2/pt unknown
- 2020-07-29 US US17/631,825 patent/US12570715B2/en active Active
- 2020-07-29 TW TW109125668A patent/TWI881992B/zh active
-
2022
- 2022-01-30 IL IL290227A patent/IL290227A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527267A5 (https=) | ||
| JP2022523554A5 (https=) | ||
| JP2022524994A5 (https=) | ||
| JP2022524993A5 (https=) | ||
| JP2022523552A5 (https=) | ||
| JP2022523971A5 (https=) | ||
| JP2022523553A5 (https=) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| Baxevanis et al. | Cancer immunotherapy | |
| Batlevi et al. | Novel immunotherapies in lymphoid malignancies | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2022524992A5 (https=) | ||
| JP2022531911A (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| EP3773621A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2022543059A5 (https=) | ||
| US20170232070A1 (en) | Combination Methods for Immunotherapy | |
| JP2022521183A5 (https=) | ||
| JP2021512637A5 (https=) | ||
| WO2021223720A1 (zh) | 人源化cd19抗体及其应用 | |
| JP2020533962A5 (https=) | ||
| CA3052803A1 (en) | Maximizing t-cell memory and compositions and methods therefor | |
| JP2023542528A5 (https=) |